Nikola Tripkovic
About Nikola Tripkovic
Nikola Tripkovic serves as the Medical Director for Europe at AlloVir, specializing in cellular therapy. He has held various medical leadership positions across notable pharmaceutical companies, including Takeda and Sobi, and has a strong background in compliance management.
Current Role at AlloVir
Nikola Tripkovic serves as the Medical Director for Europe and the Middle East at AlloVir since 2021. In this role, he focuses on advancing the company's initiatives in cellular therapy, particularly in the area of allogeneic and off-the-shelf virus-specific T cell (VST) therapy. His leadership is instrumental in guiding the medical strategy and ensuring compliance with regulatory standards across the region.
Previous Experience at Takeda
Prior to joining AlloVir, Nikola Tripkovic worked at Takeda as the Global Medical Lead for Haemophilia and Thrombotic Thrombocytopenic Purpura (TTP) from 2018 to 2021. Based in Zug, Switzerland, he was responsible for overseeing medical affairs and strategic initiatives related to these conditions, contributing to the company's global medical strategy.
Medical Leadership at Sobi
Nikola Tripkovic held the position of Medical Director for Elocta at Sobi - Swedish Orphan Biovitrum AB from 2017 to 2018. His role involved managing medical affairs for haemophilia, where he contributed to the development and execution of medical strategies in the Zürich area, Switzerland.
Educational Background
Nikola Tripkovic studied medicine at the University of Belgrade, School of Medicine, where he completed his degree from 1996 to 2003. He furthered his education by completing the PLAB/The UK Certification Exams from 2003 to 2005. Additionally, he studied at the London School of Hygiene and Tropical Medicine, U. of London, enhancing his knowledge in public health and medical practices.
Expertise in Cellular Therapy
Nikola Tripkovic specializes in cellular therapy, with a particular focus on allogeneic and off-the-shelf virus-specific T cell (VST) therapy. His expertise in this emerging field reflects a significant transition in his career from previous roles centered on haemophilia, showcasing his adaptability and commitment to advancing medical science.